Company / Return on Equity (ROE)
NOVAVAX INC Return on Equity (ROE) History
FY2016-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-66.7%
FY2022
5-year range
-66.7% / -66.7%
FY2018-FY2022
Trend
-
vs FY2021
Sector context
#153 of 190
Health Care
What the data says
NOVAVAX INC reports negative total equity of -66.7% in FY2022. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-66.7% in FY2022 with a 5-year CAGR of -13.1%.
Declined from -53.6% to -66.7% over the past 5 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -13.1pp
- 10-Year Change
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 190This company -66.7% Sector average -50.4%
▼
-32.2% below sector average
Key checks
Key Insights
- Currently 16.3pp below the Health Care sector average.
Company context
Key Data Points
- Altman Z-Score -0.87 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.5%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | -66.7% | - |
| FY2021 | - | - |
| FY2020 | -66.7% | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | -53.6% | -48.4% |
| FY2016 | -36.1% | -41.2% |
As of FY2022 · SEC 10-K · Updated Jun 30, 2026